Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Feb 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2017.
- 06 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2017.